TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07219212: A Study of JNJ-90301900 in Combination With Concurrent Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

Sponsor: Johnson & Johnson Enterprise Innovation Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 45 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT07219212 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07219212 Rescue Dossier →